High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents

[1] Bunchorntavakul C(2015)Management of patients with hepatitis C infection and renal disease World J Hepatol 7 213-225

[2] Maneerattanaporn M(2016)Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Lancet Gastroenterol Hepatol 2 161-176

[3] Chavalitdhamrong D(2016)Hepatitis C virus infection and chronic kidney disease: time for reappraisal J Hepatol 65 S82-S94

[4] Cacoub P(2012)The evidence-based epidemiology of HCV-associated kidney disease Int J Artif Organs 35 621-628

[5] Desbois AC(2015)A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection J Viral Hepat 22 897-905

[6] Isnard-Bagnis C(2007)Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease Arch Intern Med 167 1271-1276

[7] Rocatello D(2014)Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies J Viral Hepat 21 681-689

[8] Ferri C(2016)Hepatitis C virus infection in chronic kidney disease J Am Soc Nephrol 27 2238-2246

[9] Fabrizi F(2015)Transplanting hepatitis C-positive kidneys N Engl J Med 373 303-305

[10] Dixit V(2017)Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents Transplantation 101 1704-1710

[1] Bunchorntavakul C(2015)Management of patients with hepatitis C infection and renal disease World J Hepatol 7 213-225

[2] Maneerattanaporn M(2016)Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study Lancet Gastroenterol Hepatol 2 161-176

[3] Chavalitdhamrong D(2016)Hepatitis C virus infection and chronic kidney disease: time for reappraisal J Hepatol 65 S82-S94

[4] Cacoub P(2012)The evidence-based epidemiology of HCV-associated kidney disease Int J Artif Organs 35 621-628

[5] Desbois AC(2015)A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection J Viral Hepat 22 897-905

[6] Isnard-Bagnis C(2007)Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease Arch Intern Med 167 1271-1276

[7] Rocatello D(2014)Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies J Viral Hepat 21 681-689

[8] Ferri C(2016)Hepatitis C virus infection in chronic kidney disease J Am Soc Nephrol 27 2238-2246

[9] Fabrizi F(2015)Transplanting hepatitis C-positive kidneys N Engl J Med 373 303-305

[10] Dixit V(2017)Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents Transplantation 101 1704-1710